NCT03439475|Unknown
AMG 714 Expanded Access Program
1 other identifier
AMG714 Expanded Access Program
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredFeb 2018
Brief Summary
Expanded access requests for AMG 714 may be considered for adult patients with biopsy proven Refractory Celiac Disease Type II who have failed all available treatment options and do not have EATL. To request access, use Responsible Party contact information provided in this record.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 14, 2018
Completed6 days until next milestone
First Posted
Study publicly available on registry
February 20, 2018
CompletedLast Updated
May 4, 2025
Status Verified
March 1, 2025
First QC Date
February 14, 2018
Last Update Submit
May 1, 2025
Conditions
Keywords
Refractory Celiac Disease Type II
Interventions
AMG 714BIOLOGICAL
Eligibility Criteria
Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Amgenlead
MeSH Terms
Conditions
Celiac Disease
Interventions
AMG-714
Condition Hierarchy (Ancestors)
Malabsorption SyndromesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesMetabolic DiseasesNutritional and Metabolic Diseases
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 14, 2018
First Posted
February 20, 2018
Last Updated
May 4, 2025
Record last verified: 2025-03